Zoar Ltd has taken a significant step by filing a registration statement for a business combination with Impact BioMedical Inc. This merger, set to be voted on at a special meeting, highlights a trend of consolidation in the pharmaceutical preparations industry. The outcome of this merger could reshape the competitive landscape, particularly for Impact's shareholders and stakeholders.

Zoar Ltd, classified under SIC 2834 for Pharmaceutical Preparations, is an emerging growth company incorporated in the Cayman Islands. Its recent filings include a Form 424B3 on October 26, 2026, which outlines the details of the proposed business combination. The company previously operated under the name Dr Ashleys Ltd until a name change in July 2025.

The filing reveals that a special meeting of Impact BioMedical’s stockholders is scheduled for November 13, 2026. The meeting will address several proposals, including the adoption of a merger and share exchange agreement between Zoar and Impact. The agreement involves merging Impact with a wholly-owned subsidiary of Zoar, with the intention of Zoar acquiring all outstanding shares of Impact.

Key proposals to be voted on include:

  • The Business Combination Proposal, which involves the merger and share exchange agreement.
  • The Corporate Document Proposal, which seeks approval of the amended and restated memorandum and articles of association of the surviving company.
  • The Director Election Proposal, to elect eight nominees to the Board of Directors.
  • The Auditor Ratification Proposal, to confirm the appointment of Grassi & Co. as the independent public accounting firm.
  • The Advisory Vote on Executive Compensation Proposal, which provides an advisory vote on executive compensation.
  • The Adjournment Proposal, allowing for the meeting to be adjourned if necessary to solicit additional proxies.

The filing indicates that the merger is subject to customary closing conditions, including approvals from both companies’ boards and stockholders. If approved, the merger will allow Zoar to operate through its subsidiaries, primarily Zoar HK and IBO, expanding its reach in the pharmaceutical sector.

Importantly, the merger will result in the Zoar Shareholder controlling a majority of the voting power of the new entity, making it a "controlled company" under NYSE Amex rules. This status allows Zoar to opt out of certain corporate governance requirements, which could impact shareholder protections.

The filing does not specify what happens next, but the upcoming special meeting will be crucial in determining the future of both companies involved. As the pharmaceutical preparations industry continues to evolve, this merger could signal further consolidation trends and competitive shifts.